FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.4  |  FHIR Version n/a  User: [n/a]

1177151000168108: Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use)


Status: current, Defined. Date: 31-Aug 2018. Module: Australian Medicines Terminology module

Descriptions:

Id Description Lang Type Status Case? Module
2633481000168118 Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) en Fully specified name Active Case sensitive Australian Medicines Terminology module
2633491000168115 Canakinumab (Novartis) 150 mg/mL injection, vial en Synonym Active Case sensitive Australian Medicines Terminology module


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) Is a Canakinumab (Novartis) true Inferred relationship Some
Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) Is a canakinumab 150 mg/mL injection, vial true Inferred relationship Some
Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) Is a trade product unit of use true Inferred relationship Some
Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) has manufactured dose form injection true Inferred relationship Some
Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) has unit of use vial true Inferred relationship Some 252659037
Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) has intended active ingredient canakinumab true Inferred relationship Some 252659036
Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) has Australian BoSS canakinumab true Inferred relationship Some 252659036

Inbound Relationships Type Active Source Characteristic Refinability Group
Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 x 1 mL vial (containered trade product pack) has TPUU True Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) Inferred relationship Some 1
Canakinumab (Novartis) 150 mg/mL injection, 1 mL vial has TPUU True Canakinumab (Novartis) (canakinumab 150 mg / 1 mL) injection, 1 mL vial (trade product unit of use) Inferred relationship Some 1

Reference Sets

Trade product unit of use reference set

Back to Start